Skip to main content
LFMD logo

LFMD · LifeMD, Inc.

Track LFMD — free
$1.45 -0.15 (-9.40%) At close · Nov 20
Market Cap
$69.84M
Shares
48.33M
Volume · Nov 20 1.58M Avg daily vol (3M) 922.28K

Price & Indicators

 

Key stats

Close
$1.45
Fri 20 Nov
Open
$1.58
Fri 20 Nov
Average volume, 30 days
1.1M
shares a session
Short interest
7.2M
15.0% of shares · 10.8 days to cover
Day range
$1.38$1.58
Open $1.58 Close $1.45
52-week closing range
$1.45$5.27
Close $1.45 72.6% under the high
Short volume, last session
77%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 12
Price history
Jan 2020 to Nov 2026

Up next

Mar 8, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 12
Earnings call
Revenue misses guidance as 2026 outlook is cut

LifeMD reported third-quarter revenue of $44.6 million, below $48 to $51 million guidance, and cut 2026 revenue guidance to $188 million to $191 million from $205.5 million to $212.5 million. Adjusted EBITDA was a $0.4 million loss.

3 source passages
With that, revenue for the third quarter was $44.6 million, below our guidance range of $48 to $51 million, and down approximately 7% from $47.7 million in the prior year period. Adjusted EBITDA, a non-GAAP measure we define as income or loss attributable to common stockholders before various items, as outlined in today's news release, was nearly break-even with a loss of $0.4 million and within our guidance range. For the full year 2026, that equates to revenue of $188 million to $191 million and adjusted EBITDA of negative $12.6 million to negative $10.6 million. Compared with the prior guidance of $205.5 million to $212.5 million and negative $6 million to breakeven. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue declines as gross margin compresses

LifeMD reported third-quarter revenue of approximately $44.6 million, down 7%, and gross profit of approximately $36.4 million, down 11%, as telehealth costs rose to 18% of revenue from 15%.

Revenue $44.63M ▼ 6.5% Net loss $4.47M Diluted EPS -$0.11
Read from the MD&A section
4 source passages
LifeMD is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. Revenues for the three months ended September 30, 2026 was approximately $44.6 million, a decrease of 7% compared to approximately $47.7 million for the three months ended September 30, 2025. Telehealth costs were 18% of associated telehealth revenues during the three months ended September 30, 2026 compared to 15% of associated telehealth revenues during the three months ended September 30, 2025. Gross profit decreased by 11% to approximately $36.4 million for the three months ended September 30, 2026 compared to approximately $40.7 million for the three months ended September 30, 2025. Open the document at this passage
Nov 12
Current report 8-K Events of Nov 9
Secured $12.5 million loan replaces Citizens credit facility

LifeMD closed a $12.5 million secured loan on November 9, 2026 and terminated its Citizens credit facility with no amounts outstanding; the loan matures May 1, 2030 at the greater of 4.50% plus the Prime Rate or 11.50%.

Entered into a material agreement, Financial results, New debt or off-balance-sheet obligation, Unregistered sale of equity, Regulation FD disclosure Read from the first part of this long document
4 source passages
On November 9, 2026, LifeMD, Inc. (the “Company”) and its subsidiaries LFMD Pharmacy Holdings, LLC, LFMD Pharmacy Holdings 1, LLC, and LFMD Pharmacy Services, LLC (collectively, the “Borrower”) entered into and closed on a Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P., as a lender and as administrative agent and collateral agent, and Avenue Growth Lending Fund III, L.P. (together with Avenue Venture Opportunities Fund II, L.P., the “Lenders”), and a Supplement to the Loan and Security Agreement (the “Supplement,” and together with the Loan and Security Agreement, the “Loan Agreement”), pursuant to which the Lenders made a loan to the Borrower in an aggregate principal amount of $12.5 million (the “Loan”), secured by a security interest in substantially all of the Borrower’s assets. The Citizens Credit Facility was terminated on November 9, 2026 upon payment of the accrued but unpaid commitment fee and other fees. There were no amounts outstanding under the Citizens Credit Facility as of its termination. The Loan accrues interest at a variable rate per annum equal to the greater of (i) the sum of 4.50% plus the Prime Rate (as defined in the Supplement) and (ii) 11.50%. The Loan matures on May 1, 2030. Open the document at this passage
Nov 9
Late filing notice NT 10-Q
Quarterly filing delayed over revenue and expense corrections

LifeMD, Inc. delayed its September 30, 2026 quarterly filing because corrections require more time. Adjustments address revenue and expense recognition errors for 2024 through June 30, 2026; cash flow and cash position are unaffected.

2 source passages
LifeMD, Inc. (the “Company”) has determined that it is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Form 10-Q”) by November 9, 2026, the original due date for such filing, without unreasonable effort or expense because it requires additional time to complete its financial statements. The Company requires additional time to finalize adjustments necessary to correct the over recognition of revenue and under recognition of cost of revenue and general and administrative expenses that the Company identified. The adjustments related to the Company’s historical financial statements for quarterly and annual periods between 2024 and June 30, 2026. The required adjustments to correct these errors will not impact the Company’s cash flow or cash position. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$188.49M
Trailing 12 months
Net income (TTM)
−$636,501
Trailing 12 months
Revenue growth YoY
-6.5%
Year over year
Operating margin
-11.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-16.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$21.92M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.4%
Year over year · more shares
Price change (1Y)
-61.1%
Trailing year
Short interest
15.0%
Latest settlement · 10.8 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. LifeMD reported Q2 revenue of $47.3 million within guidance but adjusted EBITDA of a $3.5 million loss, missing its own target due to elevated customer acquisition costs and a new $39 introductory GLP-1 price; the company sharply lowered full-year 2026 guidance to $205.5M–$212.5M revenue and negative $6M to breakeven EBITDA, while reiterating a Q4 exit run rate of ~$250M revenue and ~$22M annualized EBITDA.

Bullish
  • + Recurring rebill revenue grew to ~84% of total revenue, supporting a higher-quality revenue base.
  • + Weight management pricing shift drove multi-month package selection from ~25% to ~85%, improving patient LTV.
Bearish
  • − Q2 adjusted EBITDA missed guidance at a loss of ~$3.5M due to elevated acquisition costs and the $39 introductory offer.
  • − Full-year 2026 revenue guidance cut to $205.5M–$212.5M from prior $220M–$230M.
  • − Full-year 2026 adjusted EBITDA guidance cut to negative $6M to breakeven from prior $12M–$17M.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −59%
below
Price vs 50-day avg −41%
below
RSI (14) 33
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −32%
trailing
6-month return −69%
trailing
YTD return −58%
this year
Relative strength −60%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow Distributing
-18% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
14.97% of shares out · ▼ -2.2% MoM · 10.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
97 holders — mid 3-yr range
Squeeze score 69
elevated · 0–100
Fundamentals
Excellent
Revenue growth +50%
Y/Y
Gross margin 1334%
contracting
EPS growth +142%
Y/Y
Free cash flow $6.4M
Balance sheet $36.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 90%
annualized · 1-yr
Max drawdown −73%
past year
ATR 15.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 7
Latest guidance · from the Earnings Call filed Nov 12, 2026
from the first quarter of 2026 to the first quarter of 2027
Operating expenses 30%
exiting the first quarter of 2026 to the first quarter of 2027
Operating expenses, excluding working marketing spend at least 25%
2027
Revenue 30%
Patient base 30%
the fourth quarter
Revenue Lowered $46M – $49M
Aug 5, 2026 $60M – $64M changed to Nov 12, 2026 $46M – $49M
prior qtr $44.63M midpoint +6.4% QoQ
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Revenues · Q3 $48M – $51M
Revenues · Q4 $60M – $64M
EBITDA · Q4 $3M – $6M
Women's health quarterly revenue run rate · Q4 of this year $3M – $5M
Prior guidance period ended · from the 8-K filed Aug 5, 2026
Revenue · third quarter of 2026 $48M – $51M
Guided vs delivered · last 7 settled
Revenue third quarter of 2026
guided $48M – $51M
$44.63M Miss −9.8%
Revenue Q2 2026
guided $47M – $50M
$47.28M In line
Revenue in the range of $48 million to $49 million For the first quarter of 2026
guided $48M – $49M
$50.16M Beat +3.4%
Total Revenue FY2022
guided $142M – $148M
$119.03M Miss −17.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−59% Bearish
Price vs 50-day avg
−41% Bearish
RSI (14)
33 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow Distributing
-18% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
14.97% of shares out · ▼ -2.2% MoM · 10.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
97 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $5
vs 200-day avg -59% vs 50-day avg -41%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Active Subscribers 349,744 Q3 FY2026 —
Adjusted EBITDA non-GAAP -$8,559,991 Nine Months Ended September 30, 2026 —
Telehealth costs as % of associated telehealth revenues 18% the three months ended September 30, 2026 filing —
Weight Management Program subscribers 108,000 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LFMD
LifeMD, Inc.
this stock
$69.84M -57.6% +49.8% — 15.0%
VEEV
Veeva Systems Inc
$43.10B +19.3% +28.1% 43.6 2.4%
PMDIY
Pro Medicus Ltd.
$14.81B -14.6% — — 0.0%
BTSG
BrightSpring Health Services, Inc.
$12.50B +67.8% +28.2% 34.2 5.8%
TEM
Tempus AI, Inc.
$9.86B -8.5% +83.4% — 13.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
97
% held
40.1%
Net QoQ
-2.3M sh
Top holder
FEDERATED HERMES, INC.
Held Float
View
Held by Funds
Fund positions
115
View
Short & Settlement
Short Interest Falling
Shares short
7.2M
Days to cover
10.8d
Change
-159.6K sh
View
Short Volume
Short vol %
77%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
7.8K
Value
$18.0K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
52.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$194.1M
Net income (FY)
$14.4M
EPS diluted
$0.25
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
17

LifeMD reported third-quarter revenue of approximately $44.6 million, down 7%, and gross profit of approximately $36.4 million, down 11%, as telehealth costs rose to 18% of revenue from 15%.

View
Proposed Sales
Value
$185.7K
Shares
40.0K
Filed
Mar 23, 2026
View
Exempt Offerings
Offering
$16.0M
Filed
Nov 20, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
LifeMD Reports Third Quarter 2026…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
LFMD -34.2% -32.2% -69.2% -36.9% -57.6%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -25.6% -22.9% -60.0% -28.2% -58.8%
Key facts CIK 948320 CUSIP 53216B104 13F (30d) 100 filings 84 filers Visit website Investor relations